Immix Biopharma Inc. (IMMX)
NASDAQ (CM) NASDAQ (CM) Primary 
All You Need to Know About Immix Biopharma (IMMX) Rating Upgrade to Buy
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Immix Biopharma (IMMX) Could Surge 113.58%: Read This Before Placing a Bet
The consensus price target hints at an 113.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 120.59% Upside in Immix Biopharma (IMMX): Can the Stock Really Move This High?
The consensus price target hints at a 120.6% upside potential for Immix Biopharma (IMMX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Immix Biopharma (IMMX) to Release Earnings on Monday
Immix Biopharma (NASDAQ: IMMX - Get Free Report) is projected to announce its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Immix Biopharma to post earnings of ($0.16) per share for the quarter. Individuals may visit the the company's upcoming Q4 2025 earning results page for the latest details on the
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition
Immix Biopharma (IMMX) is advancing NXC-201, a one-time CAR T therapy for AL amyloidosis, showing 95% complete/near-complete response rates and superior safety. IMMX's recent $100 million financing removes capital overhang, strengthens negotiating position, and supports a clear path toward BLA submission in mid-2026. With reasonable peak revenue scenarios ranging from $320 million to over $1 billion annually, the current sub-$400 million valuation presents further upside.
Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'
Immix Biopharma has provided only faint early signals of its flagship CAR T-cell therapy in AL amyloidosis. However, an upcoming data presentation at ASH should shed more light on the prospects of a potential FDA submission in 2026. Cash remains an issue, although IMMX has secured funding through a strategic investment to get them through the next few quarters.
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Immix Biopharma (IMMX) a New Buy Stock
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
